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Background. Somatostatin receptors (SSTRs) are over-expressed in several tumors making it possible for imaging with labelled
SSTR. A previous study showed feasibility to image oesophageal cancer with SSTR analogue 99mTc-depreotide. Purpose.( 1 )T o
investigate expression of the SSTRs in diﬀerent types of esophageal carcinoma and (2) to correlate such an expression with
99mTc-depreotide uptake in these lesions. Material and Methods. Total 28 patients (17 with esophageal cancer and 11 with
Barrett’s esophagus) were examined with 99mTc-depreotide scintigraphy. The SSTR2A, SSTR2B, SSTR3, and SSTR5 were analyzed
immunohistochemically in the lesion samples. Results. Among the patients with adenocarcinoma 10/11 expressed diﬀerent
amountsofSSTRs,whileSSTRswereabsentin5/6patientswithSquamouscellcarcinoma(Sqcc).Therewasnocorrelationneither
between the 99mTc-depreotide uptake and the amount of SSTRs nor between the amount of SSTRs and diﬀerentiation grade of
the tumor. Conclusions. (1) SSTRs are expressed in esophageal carcinoma and more abundantly so in adenocancer specimens; (2)
in vivo 99mTc-depreotide uptake does not obviously correlate with the immunohistochemically detection of SSTRs of diﬀerent
subtypes in esophageal carcinoma.
1.Introduction
Cancer arises through a variety of mechanisms, and these
diﬀerent processes play an important role in tumour devel-
opment and spread. By deﬁning key pathways in those
proliferative processes, the ambition has been to make it
possible to target speciﬁc metabolic pathways or receptor
steps, allowing tumour detection and collection of prognos-
tic information relevant for diagnosis as well as treatment.
Somatostatin receptors (SSTRs) occur in normal tissues
like the brain, gastrointestinal channel, endocrine pancreas,
kidneys, spleen, prostate, and thyroid. It is known that
SSTRs can also be distinctly expressed in several tumours
such as neuroendocrine tumours [1], tumours of the central
nervous system, breast cancer, and lymphoid tissue [2, 3].
Somatostatin receptors are divided in six diﬀerent subtypes:
SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4, and 5 [4–6]. It
is currently unclear to what degree and extent diﬀerent
receptor classes are expressed and overexpressed in the
various neoplastic disease states.
In this study, we investigated whether there was any
correlationbetweentheconcentrationofsomatostatinrecep-
tors SSTR2A, SSTR2B, SSTR3, and SSTR5 in squamous
cell carcinoma (SCC) and adenocarcinoma (Ac) compared
to patients with Barrett’s oesophagus without cancer. We
investigated whether there was any correlation between these2 Radiology Research and Practice
SSTRs and 99mTc-depreotide uptake. We studied whether
there was any correlation between these SSTRs and the
diﬀerentiation grade of the tumour.
DepreotideisasomatostatinanaloguebindingtoSSTR2,
3, and 5 on cell surfaces. 99mTc-depreotide scintigraphy has
been shown to be a potentially valuable tool in the diagnosis
of solitary pulmonary nodules and lymph node metastases
[2, 7–10]. Our initial experience has also revealed that
scintigraphic examination with 99mTc-depreotide is feasible
for imaging of oesophageal cancer [11].
The purposes of the present study were (1) to investigate
whether the SSTRs are expressed in diﬀerent types of
oesophageal carcinoma as assessed by use of established
immunohistochemical techniques; (2) to determine whether
in vivo estimated 99mTc-depreotide uptake correlates with
the immunohistochemical detection of SSTRs of diﬀerent
subtypes in oesophageal carcinoma; (3) to explore whether
there is a correlation between the expression of these SSTRs
and the grading of the tumour; (4) ﬁnally, to address
the question of whether the adenocarcinoma precursor
condition,intheformofBarrett’soesophagus,containsthese
receptors, which can be displayed by 99mTc-depreotide scin-
tigraphy.
2.MaterialandMethods
2.1. Patients. Twenty-eight patients were enrolled in the
study (7 females and 21 males with a median age of 63 years
(range: 33–85 years)), Table 1. Among those, 17 had cancer
of the oesophagus and 11 had Barrett’s oesophagus (long
segment, i.e., ≥3 columnar-lined oesophagus). The cancer
diagnosis was established by histopathological examination
of biopsy and/or operative specimens. All patients with
Barrett’s oesophagus were diagnosed with endoscopy and
subsequent multiple biopsies.
Among those 17 patients with cancer of the oesophagus,
11 had adenocarcinoma and 6 had squamous cell carcinoma.
Six of the 11 patients with adenocarcinoma also had Barrett’s
oesophagus.
2.2. SSTR Scintigraphy. 99mTc-depreotide (740 MBq) was
administered via an antecubital vein. Single-photon emis-
sion computed tomography (SPECT) of the thorax was
performed at 2h after injection, with the arms elevated,
using three diﬀerent gamma cameras. Most of the patients
(20 of 28) were examined with a double-headed gamma
camera (E-Cam, Siemens, Erlangen, Germany) and low-
energy, high-resolution, and parallel-hole collimators, using
a 128 × 128 matrix, 64 projections through 360◦ rotation,
and an acquisition time of 40s per projection. An additional
5patientswereexaminedwithadouble-headedgammacam-
era (DST-XL; Sopha Medical Vision Scandinavia AB, Gif-
sur-Yvette, France) and low-energy, ultra-high-resolution,
and parallel-hole collimators, using the same acquisition
parameters as above. Finally, 3 patients were examined with
a three-headed gamma camera (Picker IRIX, Cleveland,
OH, USA) and low-energy, high-resolution, and parallel-
hole collimators, using a 128 × 128 matrix, 60 projections
through 360◦ rotations, and an acquisition time of 64s
per projection. Transverse slices were reconstructed with
an iterative algorithm (HOSEM v 3.5 iterative programme;
Hermes/NUD, Stockholm, Sweden) and formatted as a
128 × 128 matrix without attenuation correction. Images
were postﬁltered with a three-dimensional Fourier ﬁlter
(Butterworth ﬁlter) with a cutoﬀ frequency of 1.1cycles/cm
(order 5.00).
The results were evaluated both through visual assess-
ment and through quantitative calculations in the 2-hour
images performed twice, in April 2009 and October 2009 by
the same radiologist, who is a specialist in general radiology
and experienced in nuclear medicine, and in November 2010
by a second radiologist, who is a specialist in both general
radiology and nuclear medicine. CT scans were used for an
accurate localisation of the 99mTc-depreotide uptake and for
placement of the region of interest (ROI). On visual assess-
ment, any focal 99mTc-depreotide uptake in the region of the
known oesophageal lesion was considered pathological. The
quantitative evaluation of 99mT c - d e p r e o t i d eu p t a k ew a sp e r -
formed retrospectively on SPECT images in all 28 patients.
First, an ROI was drawn manually around the oesophageal
tumour on each slice, using small margins (Figure 1). Next,
a background ROI was drawn in healthy lung parenchyma
(Figure 1). A volume of interest (VOI) was obtained by
adding all ROIs. Inhouse software, originally developed for
volumetricmeasurementsinmagneticresonanceimagesand
implemented on a Hermes workstation (Hermes Medical
Solution AB, Stockholm, Sweden), was used to calculate the
total counts and volume of the tumour and background
VOIs, thus giving a count density [counts/cm3]. To produce
a normalised tumour uptake, each patient was normalised to
his or her own normal lung parenchyma using the formula
U = (T − B)/B,w h e r eU is the normalised uptake, T is the
count density in the tumour, and B is the count density in
the lung parenchyma.
Both intraobserver and interobserver variability for the
quantitative assessment of 99mTc-depreotide uptake in the
oesophageal lesions was low, with intraclass correlation
coeﬃcient (ICC) = 0.97 when comparing the evaluations by
the same radiologist (intraobserver) and ICC = 0.96 when
comparing the evaluations made by the two radiologists
(interobservers).
2.3. Immunohistochemistry. For immunohistochemical as-
sessment of the diﬀe r e n tS S T R s( 2 A ,2 B ,3 ,a n d5 ) ,t h eb o n d
system (Vision Bio Systems Ltd Australian, Melbourne) was
used. The antibodies were purchased from Gramsch Labora-
tories, Kirchenstraße 6, 85247 Schwabhausen, Germany.
Tissue specimens of the oesophageal tumours and biopsy
material from the patients with Barrett’s oesophagus were
processed and prepared for immunostaining by use of mon-
oclonal antibodies. The pretreatment to achieve the epitope
was performed by heat treatment and with the enzyme pro-
nase.
The tissue sample was ﬁrst treated with peroxidase. The
antibody was diluted 1000 times and the enzyme pronase
was diluted 50 microlitres in 7000 microlitres. The tissue
sample for SSTR2A and SSTR2B was pretreated with the
diluted enzyme solution and with the enhancer for 10min.Radiology Research and Practice 3
Table 1: Histopathological and immunohistochemical analysis of 28 oesophageal lesions.
Pat no Age Gender SSTR2A SSTR2B SSTR3 SSTR5 Diﬀ SCC Ac B
1 6 8 F 00002X
2 6 3 F 11112 X
3 6 4 M 00002X
4 7 5 F 00001 XX
5 7 0 M 10111 X
6 6 7 M 11113 XX
7 6 0 M 1131 — — — X
8 5 7 M 1 1 3 ————X
9 5 8 M 00003X
10 61 M 0 0 0 0 1 X
11 61 M 0 0 1 1 1 X
12 67 M 1 0 1 1 1 X
13 62 M 1 1 1 1 1 X X
14 85 F 1 1 1 1 3 X
15 58 M 1 1 1 3 1 X X
16 60 F 1 2 2 2 3 X X
17 33 M 2 2 2 1 2 X X
18 48 M 0 0 0 0 1 X
19 67 M — 0 0 2 2 X
20 78 M 1 1 2 3 — — — X
21 70 F 1 — 1 — — — — X
22 73 M 1 2 1 2 — — — X
23 60 M 0 0 0 1 — — — X
24 48 M — 0 0 — — — — X
25 62 M 1 1 1 2 — — — X
26 66 M 0 0 0 — — — — X
27 73 M 1 0 1 1 — — — X
28 65 F 2 2 2 2 — — — X
F :f e m a l e ,M :m a l e ,D i ﬀ:d i ﬀerentiation grade of the tumour, 1: low diﬀerentiation grade, 2: moderate diﬀerentiation grade, 3: high diﬀerentiation grade, SCC:
squamous cell carcinoma, and Ac: adenocarcinoma, B: Barrett’s oesophagus. SSTRs were graded no presence = 0, small amounts = 1, moderate amounts = 2,
and large amounts = 3.
(a) (b)
Figure 1: Evaluation of scintigraphic images with 99mTc-depreotide. Region of interest (ROI) was drawn manually around the oesophageal
tumour on each slice, using small margins, and a background ROI was drawn in healthy lung parenchyma.4 Radiology Research and Practice
ThetissuesampleforSSTR3waspr etr eat edwithH1=citrate
buﬀer pH = 6, without enzyme and without enhancer for
20min. and the tissue sample for SSTR5 was pretreated with
H2 = EDTA buﬀer pH = 9 without enzyme and without
enhancer for 40min.
After this pretreatment the samples were incubated with
the antibodies for 30min. at a temperature between 37◦C
and 100◦C. The development was then performed with
diaminobenzidine (DAB) and then stained with haema-
toxylin.
The Bond Polymer Reﬁne Detection System is a compact
polymer system with high sensitivity, which includes perox-
ide block, intensive DAB dyeing, and haematoxylin contrast
dyeing. This gave the dyeing high intensity combined with a
sharp deﬁnition, without the use of streptavidin and biotin.
This excluded the occurrence of nonspeciﬁc dyeing due to
the presence of endogenous biotin, which occurs in large
amounts in some tissues in the gastrointestinal channel.
During testing of the antibodies, pancreas and skin were
used as a positive control to exclude false positive results.
Both positive and negative controls were used during the
incubation and dyeing.
SSTR2A/SS800 was the antibody against SSTR2A,
SSTR2B/SS860 was the antibody against SSTR2B, SSTR3/
SS850 was the antibody against SSTR3, and SSTR5/SS890
was the antibody against SSTR5.
SSTR2A: SS800 from rabbit, COOH-terminus, titre
1:4000, speciﬁc for human, rat, and mouse; host:
rabbit. ETQRTLLNGDLQTSI.
SSTR2B: SS860 from rabbit, COOH-terminus, titre
1:4000, speciﬁc for human; host: rabbit. FRNNKN-
RKK.
SSTR3: SS850 from rabbit, COOH-terminus, titre
1:4000, speciﬁc for human; host: rabbit. QERPP-
SRVA.
SSTR5: SS890 from rabbit, COOH-terminus, titre
1:4000, speciﬁc for human; host: rabbit. CQEAT
RPRTA AANGL MQTSK L.
The enhancer was a copper intensiﬁcation. The buﬀers
used were H1 = citrate buﬀer, pH = 6, and H2 = EDTA buﬀer
pH = 9.
The (SSTR) concentration was graded as no receptor
presence = 0, that is, negative staining (grade 0). Small
amounts = 1, that is, weak staining (grade 1) or only uneven
(focally) positive. Moderate amounts = 2, that is, moderate
staining or moderate positive (grade 2). Large amounts = 3,
that is, strong positivity (grade 3).
Scoring Procedure. Thestainscoringwasmadeaftercompar-
ison of a series of photos showing negative, slight, moderate,
and strong staining results.Examples of those “standard pho-
tos” are shown in Figure 2,n or e c e p t o rp r e s e n c e ;Figure 3,
small amounts; Figure 4, moderate amounts; Figure 5,l a r g e
amounts.
2.4. Statistics. Because extreme values may bias results when
onlytwovariablesarebeingexamined,relationshipsbetween
200 µm
Figure 2: Staining SSTR3 SCC. Score 0.
200 µm
Figure 3: Staining SSTR3 adenocarcinoma. Score 1.
99mTc-depreotide uptake, tumour grade, and amount of the
diﬀerent studied SSTRs were analysed using Spearman rank
correlations. Corresponding ρ values were calculated and
considered signiﬁcant if the ρ value was less than 0.05.
To assess intraobserver and interobserver variability,
intraclass correlation coeﬃcients were determined [12]. In
the intraobserver variability, evaluations were performed
twice, 6 months apart, by the same radiologist, and the mean
value of the two uptake values was used in further analysis.
Inaddition,asecondradiologistmadeindividualevaluations
in order to assess the interobserver variability of the uptake
values of the 2-hour images.
The study protocol was approved by the Regional Ethics
Review Board in Stockholm, Sweden and the Radiation
Safety Committee at Karolinska University Hospital, Hud-
dinge.
3. Results
One radiologist measured values for 99mTc-depreotide
uptake in April 2009 and October 2009, and a second
radiologist measured these uptake values in November 2010.
Both intraobserver and interobserver variability for the
quantitative assessment of 99mTc-depreotide uptake in the
oesophageal lesions were low, with the ICC being 0.97 and
0.96, respectively.Radiology Research and Practice 5
200 µm
Figure 4: Staining SSTR3 adenocarcinoma. Score 2.
200 µm
Figure 5: Staining SSTR3 adenocarcinoma. Score 3.
Immunohistochemical detection and semiquantitative
assessment of the diﬀerent SSTRs and 99mTc-depreotide
uptake in 11 patients with adenocarcinoma are present
in Table 2, those of the 6 patients with SCC are present
in Table 3, and those of the 11 patients with Barrett’s
oesophagus withoutcancerin Table 4. Thesummaryof these
results is shown in Table 5. Among the 6 patients with SCC,
only one patient displayed SSTR5, and the remaining 5
patients were devoid of SSTRs. Among the patients with
adenocarcinoma, the majority expressed low amounts of
SSTRs; one patient had none, a few had moderate amounts,
and only one patient expressed high amount of SSTR5.
Concerning the relationship between SSTR expression
and tumour grading, we were unable to reveal a correlation
between the diﬀerentiation of the tumour and the expression
ofSSTRs,foreitherAcorSCC.Anexceptionwasasigniﬁcant
(ρ ≤ 0.05) correlation (r = 0.70) between the presence
of SSTR2B and the grading of the Ac; the higher amount of
SSTR2B, the higher the grading of the tumour.
Overall, we observed signiﬁcantly lower levels of SSTR2A
SSTR2B, SSTR3, and SSTR5 in SCC compared to Ac (ρ =
0.001, ρ = 0.019, ρ = 0.0002, ρ = 0.047, resp.).
The majority of the patients with Barrett’s oesophagus
expressed SSTRs in their columnar epithelium. The semi-
quantitative scoring on the abundance of SSTR did not
reveal any separation of those epithelium with dysplastic
morphological changes from those without.
We were unable to reveal any correlation between the
99mTc-depreotide uptake and the expression of any of the
examined SSTRs in the 17 patients with cancer of the
oesophagus.
There was a tendency for low-diﬀerentiated tumours to
have higher 99mTc-depreotide uptake compared to highly
diﬀerentiated Ac tumours, but this diﬀerence did not reach
statistical signiﬁcance.
SCC seemed to express lower 99mTc-depreotide uptake
compared to adenocarcinoma, but this diﬀerence could not
be statistically substantiated.
Cases showing positive uptake with the scintigraphic
method but negative results in the immunohistological
analysis displayed no remarkable degree of inﬂammation
on histopathological examination of the tissue specimens.
Neither did we observe an SSRT immunostaining of the
inﬂammatory cells present in the specimens, or even the
noninﬂammatory cells (stroma cells, vessels, and others).
Among the patients with Barrett’s oesophagus, 5 had
either high or low grade of dysplastic changes in the
columnar epithelium. There was a tendency towards higher
99mTc-depreotide uptake in the epithelium with dysplasia
than in that without dysplasia, but again, this diﬀerence
could not be statistically veriﬁed.
4. Discussion
O u rp r e v i o u ss t u d i e si np a t i e n t sw i t hn o n s m a l lc e l ll u n g
carcinoma (NSCLC) showing increased 99mTc-depreotide
uptake on scintigraphic images and immunohistochemically
detected expression of SSTR2A [13]e n c o u r a g e du st oi n v e s -
tigate patients with oesophageal carcinoma. The idea was
based on similarity of cancer types, for example, SCC and
identical localisation within the thoracic cavity. As our pilot
study [11], we showed that it was feasible to image SCC and
alsoAcoftheoesophaguswithsomatostatinreceptorscintig-
raphy, utilising 99mTc-depreotide. Thereafter, we continued
to explore the tissue correlate to these in vivo observations
byimmunostainingofdiﬀerentsomatostatinreceptorsinthe
respective tumours and even in a precancerous condition.
Oneimportantprerequisiteforthepotentialimplementation
of the scintigraphy technology was the high level of intra-
as well as interobserver agreement in the assessments.
However, coming back to the originally formulated issues,
the following messages seem to be justiﬁed.
(1) SSTRs are expressed in oesophageal carcinoma and
more abundantly so in adenocarcinoma specimens.
(2) In vivo 99mTc-depreotide uptake does not obviously
correlate with the immunohistochemical detection
of SSTRs of diﬀerent subtypes in oesophageal carci-
noma.
(3) There is a questionable and clinically irrelevant cor-
relation between the expression of these SSTRs and
the grading of adenocarcinoma.6 Radiology Research and Practice
Table 2: Depreotide uptake and immunohistochemical analyses of 11 adenocarcinomas of the oesophagus.
Pat no SSTR2A SSTR2B SSTR3 SSTR5 Grade of diﬀerentiation Barrett’s Depreotide uptake
2 1 1 1 1 Intermediate — 235.84
4 0 0 0 0 Low yes 208.29
5 1 0 1 1 Low — 307.14
6 1 1 1 1 High yes 8.52
11 0 0 1 1 Low — 12.40
12 1 0 1 1 Low — 173.17
13 1 1 1 1 Low yes 160.64
14 1 1 1 1 High — 58.41
15 1 1 1 3 Low yes 109.19
16 1 2 2 2 High yes 111.77
17 2 2 2 1 Intermediate yes 12.31
Table 3: Depreotide uptake and immunohistochemical analyses of 6 SCCs of the oesophagus.
Pat no SSTR2A SSTR2B SSTR3 SSTR5 Grade of diﬀerentiation Barrett’s Depreotide uptake
1 0 0 0 0 2 — 40.38
3 0 0 0 0 2 — 137.38
9 0 0 0 0 3 — 62.84
10 0 0 0 0 1 — 107.99
18 0 0 0 0 1 — 37.02
19 — 0 0 2 2 — 82.13
SSTR expression was graded as none = 0, small amounts = 1, moderate amounts = 2, and large amounts = 3.
(4) Finally, we found that Barrett’s columnar epithelium
contains these receptors, which can be displayed by
99mTc-depreotide scintigraphy.
Based on the fact that the columnar epithelium of the
stomach harbours substantial amounts of somatostatin cells
(D cells), it came as no surprise that we found SSTRs in
adenocarcinomas and Barrett’s oesophagus, but not in SCC.
The variability among tumours and patients was unpre-
dictable, and therefore, it can be assumed that our initial
theory of introducing the idea that SSTRs are involved in key
pathways for the development of these neoplastic processes
cannot be supported by the present ﬁndings. The robustness
and strength of these observations are reinforced by the fact
that we carefully investigated many of the other subtypes of
SSTRs, not previously determined for patients with NSCLC
[13], such as SSTR2B, SSTR3, and SSTR5. Moreover, we
were unable to ﬁnd a clear correlation between the SSTR
expression and the dysplasia scorings of the Barrett’s cases.
The present observation that in adenocarcinomas there
might be an association between the grading of the tumour
and the intensity of some of the somatostatin receptors to be
stainedcanbeeitheraﬁndingobtainedbychanceoralogical
result, based on the reasonable assumption that the more
diﬀerentiatedthetumouris,themorecloselyitresemblesthe
“normal” columnar epithelium, where the D cells are quite
abundant.
The expression of SSTRs of diﬀerent subtypes in the
presently investigated patients with oesophageal carcinoma
did not correlate with the 99mT c - d e p r e o t i d eu p t a k eo n
the scintigraphic imaging. This is in accord with our
previous study on patients with NSCLC [13]. Attempts
have been made to explain and understand why tumours
with high uptake of labelled somatostatin receptor analogue
99mTc-depreotide in scintigraphic images do not regularly
express SSTRs on immunohistochemical examination of
relevant tissue specimens. Kwekkeboom et al. [14]a n d
Machac et al. [15] suggested that the 99mTc-depreotide
uptake on scintigraphic images may be due to the presence
of accompanying leucocytes or activated neuroendocrine
cells around the tumour cells [14] or in the surrounding
granulomatous tissue [15]. We tried to clarify this option
by examining thoroughly the blocks from every one of our
patients, concerning signs of inﬂammation and the content
of inﬂammatory cells, stroma cells, and vessels. Doing that,
we could not observe any deviation in a direction that
could explain the lack of correlation between uptake and
the SSTR density. What other explanations to these ﬁndings
can be considered? Is it possible that 99mTc-depreotide
scintigraphy is more sensitive to detecting SSTRs than
the corresponding immunohistochemical methods used?
Does 99mTc-depreotide bind nonspeciﬁcally to structures or
receptors on the cell surface other than those residing in
the D cells? Is expression of SSTRs a dynamic or stable
process,andwhichofthesearepickedupbythescintigraphic
technology? Many questions remain to be answered before
this method could be implemented in clinical practice.
We noted a tendency towards low-diﬀerentiated tumours
having higher 99mTc-depreotide uptake, and this could
be caused by nonspeciﬁc binding to areas of the cellRadiology Research and Practice 7
Table 4: Depreotide uptake and immunohistochemical analyses of 11 long segment Barrett’s patients without cancer.
Pat no SSTR2A SSTR2B SSTR3 SSTR5 Depreotide uptake
7 1 1 3 1 52.52
81 1 3 — 0
20 1 1 2 3 40.36
21 1 — 1 — 28.19
22 1 2 1 2 9.86
23 0 0 0 1 31.86
24 — 0 0 — 5.96
25 1 1 1 2 0.86
26 0 0 0 — 0
27 1 0 1 1 56.45
28 2 2 2 2 1.35
SSTR expression was graded as none = 0, small amounts = 1, moderate amounts = 2, and large amounts = 3.
Table 5: Summary of the 99mTc-depreotide uptake and immunohistochemically determined SSTRs.
Diagnosis SSTR2A average SSTR2B average SSTR3 average SSTR5 average Depreotide average uptake
Adenocarcinoma 0.9 0.8 1.1 1.2 127.1
Squamous cell carcinoma 0 0 0 0.3 78.0
Barrett’s oesophagus 0.9 0.8 1.3 1.7 20.1
surface, which could be more common on tumour cells
with low diﬀerentiation compared to high diﬀerentiation.
This corresponds to our previous observations in NSCLC
[13], where poorly diﬀerentiated tumours had a higher
99mTc-depreotide uptake. However, this tendency was not
statistically signiﬁcant, either [13]. In order to explore
corresponding relationships in more detail, much larger
study cohorts are required.
Concerning patients without cancer but with a pre-
cancerous condition, these were enrolled because it would
be of special value to have a tool that could aid in the
early detection of those who will subsequently develop
neoplasia. Although we found somewhat higher 99mTc-
depreotide uptake in patients with dysplasia compared to
those without, the overlap was substantial. Even in the
immunohistochemical analysis, the tendency was there to
show that those with dysplasia more often expressed SSTRs
(16 of 17) compared to those without dysplasia (13 of
21). The clinical value of these ﬁndings has to be further
exploredandsubstantiatedinlargerpatientsamplesandwith
longitudinal evaluation.
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